Conor launches countersuit against Angiotech:
This article was originally published in Clinica
Conor Medsystems, the Nasdaq-listed, Menlo Park, California-based developer of drug-eluting stents, has launched legal proceedings in the UK against Canadian firm Angiotech Pharmaceuticals. Conor wants the court to revoke Angiotech's European patent relating to stents coated with paclitaxel and a polymer carrier. Its challenge follows Angiotech's filing of a joint lawsuit with DES partner Boston Scientific against Conor earlier this month, accusing the latter of infringing the patent in question. Vancouver-based Angiotech said it expected Conor to "take various defensive acts", against which it would defend itself "to the fullest".